Long-term follow-up data have just been published from two studies designed to provide preliminary information on the potential use of very aggressive forms of treatment in men with high-risk categories of prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: aggressive, androgen deprivation, docetaxel, hormone, paclitaxel, radiation, taxane, therapy | 7 Comments »
Today’s news reports summarize papers recently published on:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", estradiol, hormone therapy, HRQOL, optimism, outcomes, paclitaxel, pessimism, quality of life, radiation, radical prostatectomy | Leave a comment »
A number of trials are currently evaluating the potential value of adjuvant chemotherapy after first-line treatment in men with high-risk prostate cancer. The effects of this form of treatment on long-term outcomes still to be established, but … … READ MORE …
Filed under: Management, Treatment | Tagged: "high risk", adjuvant, chemotherapy, paclitaxel | Leave a comment »
A group at the Cleveland Clinic has reported the results of a small, single-arm, Phase II trial of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel or neoadjuvant Abraxane®), given prior to radical prostatectomy in high risk, locally advanced patients. Prior comparable studies with neoadjuvant docetaxel have demonstrated a PSA response but have shown no obvious antitumor activity. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", Abraxane, locally advanced, neoadjuvant, paclitaxel | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 